Skip to Main Content

Paper Details

Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial.
Clin Cancer Res
2
2023
Author NameAffiliation
Peter A FaschingUniversity Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-EMN
Jan BudcziesInstitute for Pathology, Heidelberg University Hospital
Hans-Peter SinnInstitute for Pathology, University Hospital Heidelberg
  • 1 - 3

Datasets

Release 1.2